This Blanket Purchase Agreement (BPA) is a federal contract Indefinite Delivery Vehicle (IDV) awarded by the National Acquisition Center, a civilian agency, to Merck Sharp & Dohme LLC, doing business as Merck. The BPA has a ceiling value of $15,000,000 and an ultimate completion date of August 8, 2025. It was awarded on August 9, 2022 and is not set-aside.
The primary purpose of this BPA is the procurement of the pharmaceutical product Welireg (belzutifan) from Merck, a major pharmaceutical manufacturer and supplier to the U.S. federal government. Merck has a long history of providing a wide range of vaccines, drugs, and medical countermeasures to support public health initiatives and healthcare missions across multiple federal agencies, including the Department of Veterans Affairs, Department of Defense, Department of Health and Human Services, and the Centers for Disease Control and Prevention. This BPA specifically supports the Department of Veterans Affairs in obtaining Welireg, which is used for cancer treatment. The flexible nature of the BPA allows the agency to order Welireg as needed over the multi-year period of performance.
Generated 12/13/24, 9:06 AM